Business Standard

BS Reads: Lessons for India Inc from cricket win and slow vaccine embrace

While Team India's can-do attitude in the face of imminent loss got them top honours, Serum and Bharat Biotech failed to gauge the impact of exogenous factors on two high-potential health products

India cricket team after Brisbane Test
Premium

Ajinkya Rahane leads team India at victory march at The Gabba, Brisbane. Photo: @ICC

George Skaria New Delhi
India’s dramatic cricket victory at the Gabba, Australia, and her underwhelming Covid-19 vaccine adoption in the country are classic cases of how risk was managed differently in two instances. One offered a positive outcome and the other a not-so-optimistic one.

The first demonstrated how a young, freshly-minted team raring to go could overcome the risks of possible failure with a can-do attitude and the latter showed how two Indian vaccine makers who bet big on a high market potential healthcare product were caught off-guard by controversies and exogenous events, especially from the media and the government.

What then are the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 23 2021 | 8:36 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com